RxDoctor Payments Data

Larry Bush, MD

Infectious Disease · Atlantis, FLNPI 1689657090

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,660 of the $25,520 with a category attached, or 96.6%. Merck accounts for 96.6% of it on its own, with 5 other manufacturers making up the rest. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,520in general payments, 2019–2025

Across 78 payments — averaging $327.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$25K
  • Gilead$448
  • Viiv Healthcare Company$195
  • Janssen Products, LP$174
  • Johnson & Johnson$28
  • Nabriva Therapeutics, PLC$14
$9,254,137in research payments, 2019–2025

Across 174 payments — averaging $53,185 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$4M
  • Janssen Research & Development, LLC$3.6M
  • Merck$841K
  • Astrazeneca UK Limited$318K
  • Johnson & Johnson$207K
  • GSK$202K
  • plus $61K from 1 others

What the payments were for

  • Consulting fees$24,66097%
  • Food & beverage$6583%
  • Education$2021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$25,520 in reported general payments places this provider in the 90th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$151,033
Medicare patients
296
Services billed
1,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala337$1,339,088
DovatoDolutegravir Sodium/Lamivudine412$1,241,037
OdefseyEmtricitab/Rilpiviri/Tenof Ala88$334,501
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf67$312,979
JulucaDolutegravir/Rilpivirine85$299,508
DescovyEmtricitabine/Tenofov Alafenam39$83,989
PrezcobixDarunavir/Cobicistat27$65,454
IsentressRaltegravir Potassium29$59,911
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,022
TivicayDolutegravir Sodium21$46,214
Etravirine12$12,664
Rifabutin12$6,581
Lamivudine-ZidovudineLamivudine/Zidovudine30$5,307
Daptomycin12$4,776
Vancomycin Hcl18$3,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Tivicay$195$1,586,759518 claims
GileadBiktarvy, Descovy, Genvoya$448$1,471,099388 claims
Janssen Products, LPSymtuza$174$312,97967 claims
Johnson & JohnsonPrezcobix$28$65,45427 claims
MerckIsentress$24,660$59,91129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →